Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
December 22, 2025
SABCS Conference 2025 Poster
Share
Wobble Genomics, a biotechnology company focused on improving cancer outcomes through better diagnosis and therapy selection, presented new data at the 2025 San Antonio Breast Cancer Symposium (SABCS), (December 9-12), in San Antonio, Texas. The data demonstrates the ability to accurately detect HER2 expression in breast cancer, both in solid tumour biopsies and blood samples.
The new data confirm the platform’s ability to determine HER2 status with high fidelity from breast cancer tissue, providing detailed isoform-level profiles, and show a correlation with HER2 immunohistochemistry (IHC) scores. The study also establishes the potential of Wobble’s long-read RNA technology to determine HER2 targeted therapy selection from blood.
These findings provide valuable insights into transcript diversity and expression patterns, enabling improved diagnostic accuracy and refining therapy selection. This will allow for a more precise understanding of tumour biology, enabling better-informed decisions for selecting the most appropriate therapy for breast cancer patients.
Dr Richard Kuo, CEO and Founder of Wobble Genomics, commented: “Our research highlights the significant promise of our platform, offering a new level of precision in cancer diagnostics by providing detailed isoform-level insights into HER2 expression. These findings could enable clinicians to make more informed therapy choices, leading to safer, more personalised care for patients”.
Our latest data demonstrates a limit of detection more than an order of magnitude better than the current industry benchmark, while maintaining 100% molecular specificity at that level of sensitivity
This research demonstrates the potential of liquid biopsy to enable more precise, non-invasive treatment selection, helping match patients to the most effective therapies while reducing reliance on invasive tissue biopsies.
This poster presents the development and analytical validation of a novel long-read RNA sequencing platform designed to detect low-abundance cancer transcripts directly from whole blood. By overcoming key limitations of traditional short-read approaches, the technology enables sensitive, full-length profiling of both short and long RNA species, even within complex biological backgrounds. The study demonstrates strong performance in detection sensitivity, precision, and transcript coverage, while also highlighting the platform’s ability to uncover clinically relevant isoforms in important cancer genes such as HER2 and TROP2. Collectively, these advances position the platform as a powerful tool for liquid biopsy applications, supporting improved cancer diagnostics, treatment monitoring, and precision medicine development.
-
Wobble Genomics presents a highly sensitive long-read transcriptomics platform for non-invasive profiling of breast cancer from blood. Leveraging its proprietary Level-Up technology, the platform enables comprehensive detection of cancer-specific RNA isoforms, including clinically relevant HER2 variants, with strong concordance to tumour status. The study demonstrates the potential of liquid biopsy to refine patient stratification, expand eligibility for targeted therapies, and monitor treatment response over time—offering a powerful new approach to precision oncology.
